Investigating how Estrogen Receptor Beta can help treat aggressive breast cancer.
ERβ repurposes EZH2 to suppress oncogenic NFκB signaling in TNBC
This study is looking at how a specific receptor called Estrogen Receptor Beta (ERβ) can help slow down the growth of Triple Negative Breast Cancer (TNBC), with the hope of finding new treatments that could improve survival for patients with this type of cancer.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Mayo Clinic Rochester NIH-funded |
| Lab location | 1 site (Rochester, United States) |
| Project ID | NIH-11004997 on NIH RePORTER |
What this research studies
This research focuses on Triple Negative Breast Cancer (TNBC), a particularly aggressive form of breast cancer that currently has limited treatment options. The study explores the role of Estrogen Receptor Beta (ERβ) in TNBC, specifically how activating this receptor can inhibit cancer cell growth and spread. By using both laboratory models and patient-derived samples, the research aims to identify new therapeutic strategies that could improve outcomes for patients with ERβ positive tumors. The ultimate goal is to develop targeted therapies that can prevent disease recurrence and enhance survival rates.
Who could benefit from this research
Good fit: Ideal candidates for this research are women diagnosed with Triple Negative Breast Cancer, particularly those with ERβ positive tumors.
Not a fit: Patients with non-TNBC breast cancer subtypes or those without ERβ expression may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to new treatment options that significantly improve survival rates for patients with Triple Negative Breast Cancer.
How similar studies have performed: Previous research has shown promising results with similar approaches targeting estrogen receptors in breast cancer treatment, indicating potential for success in this area.
Where this research is happening
Rochester, United States
- Mayo Clinic Rochester — Rochester, United States (Active)
Researchers
- Principal investigator: Hawse, John R. — Mayo Clinic Rochester
- Study coordinator: Hawse, John R.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.